Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the country’s PDP programme, providing access to around 70% of public-sector demand.
We haven't written up this one. The Economic Times - Top News has the full story — the link below goes straight to it.